Table 1 CHEK2*1100delC mutation frequencies

From: The CHEK2*1100delC mutation has no major contribution in oesophageal carcinogenesis

CHEK2*1100delC mutation

 

Number tested

Carriers

Percentage

OR (95% CI)a

P-valuea

Controls

     

Netherlands (A)b

184

3

1.6

  

Netherlands (B-ERGO)b

460

6

1.3

  

Total

644

9

1.4

  

Barrett's metaplasias

99

3

3.0

2.20 (0.38–9.04)

0.23

Dysplasias

66

1

1.5

1.09 (0.02–8.05)

0.93

Adenocarcinomas

196

3

1.5

1.10 (0.19–4.45)

0.89

Squamous cell carcinomas

190

1

0.5

0.37 (0.01–2.73)

0.33

Total

551

8

1.5

1.04 (0.35–3.06)

0.94

  1. aOR: odds ratio, 95% CI: 95% confidence interval, and P-values are determined by χ2-test, as compared to frequency in controls.
  2. bCHEK2*1100delC frequency in Dutch control cohorts A and B by Meijers-Heijboer et al (2002).
Back to article page